ANEUVO brings to market advanced technology and therapies designed to help patients with diseases and injuries that have not responded to conventional medical approaches.

The ANEUVO platform springs from decades of research and work from Distinguished Professor Wentai Liu of UCLA and Yi-Kai Lo, PhD. With funding from the National Institutes of Health, National Science Foundation, and Department of Energy, the ANEUVO co-founders worked together at UCLA to leverage their experience in physiology, neuroscience, electrical engineering, neuro-engineering, and neuromodulation for new approaches to patient treatment.

As a focus of his doctoral work, Lo expanded on Professor Liu’s achievements in neuromodulation. They worked together to build a set of novel technologies for medical devices and systems to modulate the central, peripheral, autonomous, and enteric nervous systems. In 2016, Lo and Professor Liu utilized the technology from UCLA to create the company that is now ANEUVO.

By delivering a technology platform applicable to a wide range of biomedical applications, ANEUVO develops innovative therapies as the foundation for transforming research into meaningful treatments. The result is valuable options for patients who suffer from chronic and debilitating conditions such as spinal cord injury, multiple sclerosis, and gastrointestinal tract diseases.

ANEUVO’s mission is to provide advanced, non-invasive treatments and therapies that dramatically improve patients’ quality of life.

Latest News

ANEUVO receives FDA Breakthrough Device Designation

ANEUVO Awarded $999,999 from the National Science Foundation

ANEUVO CEO Yi-Kai Lo Presents at Unite 2 Fight for Paralysis